Axsome Therapeutics is preparing the imminent launch of Auvelity for the treatment of agitation in Alzheimer’s patients. This expansion introduces the product to a substantial new patient population as the company advances its key assets.
Axsome also presented new clinical data for its migraine treatment, SYMBRAVO, at the American Headache Society’s annual scientific meeting. The presentation featured post-hoc analyses regarding efficacy and patient return-to-function. It also included pooled analyses on pain relief to further establish the drug’s clinical profile.